

Supporting Information

Novel reversible and selective nerve agent simulant detection in conjunction with superoxide “turn-on” probing

Yoon Jeong Jang,^a Dhiraj P. Murale,^a David G. Churchill^{*,a}

E-mail: dchurchill@kaist.ac.kr

Experimentals

Materials and instruments

Fluorescein (Aldrich), diethyl chlorophosphate (Aldrich), diethyl cyanophosphonate (TCI) and diethyl methylphosphonate (Aldrich) are commercially available. Fluorescein was dissolved in pH 7.4 10 mM HEPES buffer and concentration was 10^{-6} M (1) and 0.1 M of DCP, DECP and DEMP were dissolved in acetonitrile. Fluorescence measurements were carried out with a Shimadzu RF-5301pc spectrofluorophotometer slit width Ex, E_m = 1.5 and 3. All solvents used in NMR spectral analyses were purchased commercially and were of spectroscopy grade. ¹H, ¹³C and ³¹P NMR spectra were measured on Bruker Avance 400 MHz spectrometer. High-resolution MALDI-TOF mass spectrometry was performed on an Applied Biosystem Voyager 4394 (Ionization method, N₂ laser (337 nm, 3 ns pulse): analyzer 2.0 m linear mode; 3.0 reflector mode)

Synthetic procedure

Compound **1** (for only Mass spectrum)

Fluorescein (200 mg, 0.602 mmol) and 1,4-diazabicyclo[2,2,2]octane (135.05 mg, 1.204 mmol) were dissolved in 15 mL of dry DMF in round bottom flask under inert atmosphere of argon for 15 min. Then, DCP (0.174 mL, 1.204 mmol) was added and the reaction was continued at room temperature for 13 hr. The reaction was quenched by 150 mL of water and kept in refrigerator overnight. After the mixture was filtered and washed twice by water and dried to get a yellow powder (184.5 mg, 50.70%)

Results




Fig. S1. ^1H NMR spectra of fluorescein in DMSO- d_6 (a), compound **1** (b), and compound **1** and KO_2 (c)

(a) ^1H NMR (400 MHz, DMSO- d_6 : 2.51 ppm) δ 8.00 (dd, $^3J_{\text{H-H}} = 7.68$ Hz, $^4J_{\text{H-H}} = 1.00$ Hz, 1H, H₉), 7.79 (m, 1H, H₅), 7.71 (m, 1H, H₆), 7.28 (dd, $^3J_{\text{H-H}} = 7.72$ Hz, $^4J_{\text{H-H}} = 0.92$ Hz, 1H, H₁₀), 6.71 (s, 2H, H₁₃), 6.56 (s, 4H, H_{7,11})

(b) ^1H NMR (400 MHz, DMSO- d_6 : 2.51 ppm) δ 8.00 (d, $^3J_{\text{H-H}} = 7.60$ Hz, 1H, H₉), 7.79 (t, $^3J_{\text{H-H}} = 7.08$ Hz, 1H, H₅), 7.71 (t, $^3J_{\text{H-H}} = 7.48$ Hz, 1H, H₆), 7.27 (d, $^3J_{\text{H-H}} = 7.6$, 1H, H₁₀), 6.79 (s, 2H, H₁₃), 6.60 (s, 4H, H_{7,11}) 3.97–3.89 (m, 8H, H_{15,16}), 1.24–1.20 (m, 12H, H_{17,18}),

(c) ^1H NMR (400 MHz, DMSO- d_6 2.52 and D₂O 4.43 ppm) δ 7.96–7.91 (m, 1H, H₉), 7.76–7.64 (m, 1H, H₅), 7.70–7.64 (m, 1H, H₆), 7.13–7.07 (m, 1H, H₁₀), 6.71–6.68 (m, 2H, H₁₃), 6.54–6.47 (m, 4H, H_{7,11}) 3.97–3.89 (m, 8 H, H_{15,16}), 1.24–1.20 (m, 12H, H_{17,18})




Diagram of fluorescein, compound **1**, and diethyl phosphoric acid




Fig. S2. ^{13}C NMR spectra of fluorescein (a), compound **1** (b), and compound **1** and KO_2 (c)

(a) ^{13}C NMR (100 MHz, DMSO-d_6 : 3.97 ppm) δ 169.2 (C_1), 160.0 (C_2), 152.9 (C_3), 152.3 (C_4), 136.0 (C_5), 130.5 (C_6), 129.5 (C_7), 126.7 (C_8), 125.0 (C_9), 124.5 (C_{10}), 113.1 (C_{11}), 110.0 (C_{12}), 102.7 (C_{13}), 83.6 (C_{14})

(b) ^{13}C NMR (100 MHz, DMSO-d_6 : 3.97 ppm) δ 169.0 (C_1), 160.6 (C_2), 152.7 (C_3), 135.8 (C_5), 130.5 (C_6), 129.6 (C_7), 126.9 (C_8), 125.3 (C_9), 124.8 (C_{10}), 113.4 (C_{11}), 110.4 (C_{12}), 102.7 (C_{13}), 65.3 (C_{14}), 62.5 (C_{15}), 62.5 (C_{16}), 16.5 (C_{17}), 16.5 (C_{18})

(c) ^{13}C NMR (100 MHz, DMSO-d_6 and D_2O : 3.97 ppm) δ 169.6 (C_1), 159.9 (C_2), 152.7 (C_3), 152.3 (C_4), 136.2 (C_5), 130.6 (C_6), 129.2 (C_7), 126.4 (C_8), 125.1 (C_9), 124.2 (C_{10}), 113.1 (C_{11}), 109.8 (C_{12}), 102.7 (C_{13}), 84.0 (C_{14}), 61.0 (C_{19}), 60.9 (C_{20}), 16.7 (C_{21}), 16.6 (C_{22})




Fig. S3. HR-MS spectra of compound **1** was observed at 627.1204 and calculated for $C_{28}H_{30}O_{11}P_2Na^+$ is 627.1156)




Fig. S4: Relative fluorescence intensity of compound **1** ($\lambda_{\text{exc}} = 490 \text{ nm}$, $\lambda_{\text{emis}} = 511 \text{ nm}$). **A** KO_2 , **B** $\text{KO}_2 + \text{H}_2\text{O}_2$, **C** $\text{KO}_2 + \text{TBHP}$, **D** $\text{KO}_2 + \text{NaOCl}$, **E** $\text{KO}_2 + \text{OH}^-$, **F** $\text{KO}_2 + \text{OtBu}^-$.




Fig. S5. Relative fluorescence intensity of compound **1** with ROS (3300 μM of KO_2 , H_2O_2 , TBHP, NaOCl , OH^\cdot , OtBu^\cdot in HEPES buffer; 10 mM, pH 7.4 $\lambda_{\text{exc}} = 490$ nm, $\lambda_{\text{emis}} = 511$ nm, slit width = 3).




Fig. S6. Emission spectra change of **compound 1** as a function of concentration DCP (0 – 3600 μM) in HEPES buffer; 10 mM, pH 7.4). Each spectrum was recorded at real time




Fig. S7 Emission titration spectra of fluorescein (10⁻⁶ M, HEPES buffer; 10 mM, pH 7.4) with (a) DCP (0 to 3300 μM), (b) DEMP (0 to 6600 μM), and (c) DECP (0 to 3000 μM) in acetonitrile $\lambda_{\text{exc}} = 490$ nm, $\lambda_{\text{emis}} = 511$ nm (slit width = 1.5)

Nerve agent	LC_{t50} Inhalation mg·min/m³	LD₅₀ Skin mg/individual
GA	200	4000
GB	100	1700
GD	100	30
VX	50	10

Table. S1 Lethal concentration & time and lethal dose of GA, GB, GD and VX¹




Fig. S8. ¹H NMR spectrum of fluorescein in DMSO-d₆




Fig. S9. ^1H NMR spectrum of compound **1** in DMSO-d_6




Fig. S10. ¹H NMR spectrum of compound 1 and KO₂ in DMSO-d₆ and D₂O




Fig. S11. ¹³C NMR spectrum of fluorescein in DMSO-d₆




Fig. S12. ¹³C NMR spectra of compound **1** in DMSO-d₆




Fig. S13. ¹³C NMR spectrum of compound **1** and KO₂ in DMSO-d₆ and D₂O

³¹P NMR/2
DCP




Fig. S14. ³¹P NMR spectrum of fluorescein in DMSO-d₆

3.99




Fig. S15. ^{31}P NMR spectrum of compound 1 in DMSO-d_6

**³¹P NMR/4
DCP+FL+KO₂**




Fig. S16. ³¹P NMR spectrum of compound **1** and KO₂ in DMSO-d₆ and D₂O

Reference

1. O. A. Sadik, W. H. Land, Jr. and J. Wang, *Electroanalysis*, 2003, **15**, 1149